EGFR tyrosine kinase inhibitors (TKIs) have been approved for the treatment of NSCLC patients with sensitive EGFR mutations, and patients have been found to have a higher response rate and longer PFS than those administered platinum‐based chemotherapy. Here, EGFR is linked to non-small cell lung carcinoma.